Drug Formulation Lab

Supporting preclinical drug formulation from concept to characterization

Overview

The Drug Formulation Lab specializes in preclinical drug formulation development. The team designs and evaluates formulations ranging from nanoparticles, microparticles, microemulsions, liposomes and nanofibers to more traditional dosage forms such as long-acting injectables, inhalation products and tablets.

Capabilities include lab-scale formulation, in vitro physicochemical characterization, stability testing, permeability studies and preclinical efficacy evaluation in animal models. The group also develops disease-specific animal models, particularly for ocular disorders, opioid use disorder, lung infection and cancer and angiogenesis. These studies support dose selection, toxicity and efficacy assessment and tissue analysis to understand drug accumulation, metabolism and elimination. The lab can also assist with small-scale pharmaceutical packaging using blister packing equipment to enable room temperature and accelerated stability studies in environmental chambers.

Equipment

Members

• Lead: Qingguo Xu, Ph.D.
• Michael Hindle, Ph.D.
• Masahiro Sakagami, Ph.D.